人类α4β2*尼古丁乙胆受体结合的年龄和性别相关差异,用[18F]尼芬PETPET评价
Andrew McVea1,2, Jihoon Choi2, Alexandra DiFilippo1,2
1Department of Medical Physics, University of Wisconsin - Madison School of Public Health, Madison, WI, United States.
Imaging neuroscience (Cambridge, Mass.)
|July 18, 2025
概括
年龄影响大脑的尼古丁乙胆受体 (nAChRs). 这项研究发现,随着年龄的增长,体中[18F]尼与α4β2* nAChRs的结合减少,而小脑结合增加. 性别没有显著影响结合.
科学领域:
- 神经科学是一个神经科学.
- 放射化学 放射化学是指辐射化学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经α4β2*尼古丁性乙胆受体 (nAChRs) 是尼古丁的关键点,并与烟草依赖有关.
- [18F]Nifene是一种正电子发射断层扫描 (PET) 放射追踪器,其特异性高于α4β2* nAChRs,可实现体内脑部成像.
- 了解影响nAChR分布的因素对于研究和临床应用至关重要.
研究的目的:
- 为了研究年龄和性别对PET放射追踪剂[F]尼与健康,非吸烟的人类参与者的α4β2*nAChRs的结合的影响.
- 为了确定[18F]尼结合模式是否在年轻人和老年人之间,以及男性和女性之间有所不同.
- 提供支持将年龄作为变量纳入α4β2* nAChR系统研究的数据.
主要方法:
- 将认知正常的参与者 (n=31) 招募到年龄 (年轻人与老年人) 和性别 (男性与女性) 的队列中.
- 计算分布体积比率 (DVRs) 对于[18F]Nifene在已知nAChR表达的大脑区域.
- 使用多参数线性回归对DVR进行比较,并对多次比较进行校正.
主要成果:
- 研究人员发现,年龄增长与lamus,特别是前核 (p < 0.001) 中的 Nifene DVR 减少之间存在显著的关联 (p < 0.001).
- 相反,年龄的增加与大脑小脑灰质中较高的[18F]尼DVR相关 (p = 0.01).
- 在统计纠正后,在[18F]尼结合中没有发现显著的性别差异.
结论:
- 年龄是影响[18F]尼芬与人脑中的α4β2*nAChRs结合的重要因素.
- 在研究和临床环境中,应考虑与年龄相关的nAChR可用性变化,特别是在乳头和小脑.
- 这些发现强调了在实验设计和对涉及α4β2* nAChR系统的研究数据分析中考虑年龄的重要性.
相关概念视频
Cholinergic Receptors: Nicotinic
3.7K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
3.7K
Adrenergic Receptors: β Subtype
2.2K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
2.2K
Adrenergic Receptors: ɑ Subtype
1.9K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.9K
Cholinergic Receptors: Muscarinic
3.1K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
3.1K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.3K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.3K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.1K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.1K


